Indecainide - CAS 74517-78-5
Catalog number: 74517-78-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20-H24-N2-O
Molecular Weight:
308.42
COA:
Inquire
Targets:
Sodium Channel
Description:
Indecainide is a Sodium channel antagonists originated by Eli Lilly. Treatment for Arrhythmias and Ventricular arrhythmias was discontinued.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Powder
Synonyms:
Ricainid, Indecainida, Indecainidum, Decabid, Ricainide;9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide
Solubility:
Soluble in DMSO
Storage:
-20℃ Freezer
MSDS:
Inquire
Application:
Arrhythmias; Ventricular arrhythmias
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
UCEWGESNIULAGX-UHFFFAOYSA-N
InChI:
1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23)
Canonical SMILES:
C1(c2c(cccc2)c2c1cccc2)(CCCNC(C)C)C(N)=O
Current Developer:
Originator Eli Lilly
1.Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia.
Podrid PJ1, Hohnloser S, Lown B. Am J Cardiol. 1988 Apr 1;61(10):764-9.
Indecainide, a new class 1C agent, was administered to 16 patients with a history of ventricular fibrillation or ventricular tachycardia. Evaluation of drug effect consisted of acute testing with 125 mg followed by a period of maintenance therapy. Efficacy, as evaluated with both ambulatory monitoring and exercise testing, was defined as total elimination of runs of ventricular tachycardia, greater than 90% reduction in couplets and greater than 50% decrease in ventricular premature complex. During acute drug testing 9 of the 16 patients responded to the drug. Four patients did not receive maintenance therapy with indecainide, because of toxic side effects. Of the remaining 12 patients, 7 responded to indecainide based on monitoring, 5 responded judged by exercise testing and 4 when both monitoring and exercise testing were considered. There was no correlation between dose, blood level of drug and effect on arrhythmia. In this small group acute drug testing did not appear to predict the response to the drug during maintenance therapy.
2.Effect of indecainide in patients with left ventricular dysfunction.
Giardina EV1, Saroff AL, Schneider M. Clin Pharmacol Ther. 1990 Nov;48(5):582-9.
Indecainide, a new antiarrhythmic agent classified as type Ic was evaluated in 11 patients with heart disease who had greater than or equal to 30 ventricular premature complexes/hour, moderate-to-marked left ventricular dysfunction, and mean ejection fraction 34% +/- 8%. Patients received indecainide, 50 mg by mouth, every 6 hours and the dose was increased until greater than or equal to 80% suppression was noted, adverse effects occurred, or a maximum dose of 100 mg indecainide was given every 6 hours. Ventricular premature complexes were suppressed greater than or equal to 80% in nine patients (p less than 0.05) and ventricular tachycardia episodes were completely suppressed in five of eight patients. The effective or maximal mean daily indecainide dose was 191 +/- 32 mg; half of the responders achieved achieved efficacy at serum drug concentration greater than or equal to 600 ng/ml. Serum drug concentration was directly related to gender (r = 0.
3.Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics.
Holland DR1, Lacefield WB, Gonzales CR, Johnston SR, Turk JA. J Cardiovasc Pharmacol. 1989 Sep;14(3):454-61.
The cardiovascular pharmacology of indecainide, a new class I antiarrhythmic agent, was studied in intact animals. Arrhythmias produced by ouabain were converted to sinus rhythm by indecainide (100 micrograms/kg/min, i.v.) at 0.7 +/- 0.1 mg/kg and a corresponding plasma concentration of 1.7 +/- 0.2 micrograms/ml at the time of conversion. Infusion at a slower rate (20 micrograms/kg/min) converted to sinus rhythm at 0.4 +/- 0.1 mg/kg and 0.4 +/- 0.2 micrograms/ml plasma. Arrhythmias produced by prior (24 h) coronary artery occlusion were converted to 50% sinus rhythm by indecainide (100 micrograms/kg/min, i.v.) at 1.3 mg/kg. In conscious dogs, 6 mg/kg indecainide p.o. prolonged the PR and QRS intervals by 31 +/- 5 and 13 +/- 3%, respectively, at a corresponding plasma concentration of 2.8 +/- 0.5 micrograms/ml. His bundle studies revealed that the PR interval prolongation was due to an increase in both A-H and H-V intervals. In anesthetized dogs, indecainide (1-5 mg/kg, i.
4.Indecainide for treatment of ventricular ectopic depolarizations: efficacy, pharmacokinetics, hemodynamic effects and safety.
Salerno DM1, Krejci J, Granrud G, Hodges M. J Am Coll Cardiol. 1988 Apr;11(4):843-50.
Ten patients were treated with oral indecainide for frequent ventricular ectopic depolarizations during a short-term, dose-ranging, single blind inpatient trial followed by open label long-term therapy for 2 years. During dose ranging, patients received placebo followed by 50, 75 and 100 mg of indecainide three times daily. Eight of the 10 patients achieved greater than or equal to 80% reduction in ventricular ectopic depolarizations during inpatient therapy. Mean ventricular ectopic depolarizations decreased from 15,792/24 h to 2,357/24 h on optimal dosage (p less than 0.01). Nine patients had paired ventricular ectopic depolarizations; four of the nine had greater than or equal to 99% reduction of these beats. Among seven patients with nonsustained ventricular tachycardia, five had 100% elimination of these events with indecainide and all had greater than or equal to 90% reduction in these events. Indecainide prolonged the PR interval 44 +/- 27 ms (p less than 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Sodium Channel Products


CAS 159138-80-4 Cariporide

Cariporide
(CAS: 159138-80-4)

Cariporide, also known as HOE-642, is a selectiveNa+/H+exchange inhibitor, also known as the Na+/H+ antiporter, which functions to improve cellular integrity fo...

CAS 550-83-4 Propoxycaine hydrochloride

Propoxycaine hydrochloride
(CAS: 550-83-4)

Propoxycaine hydrochloride is the hydrochloride salt form of Propoxycaine used to control the pain of intramuscular injection of penicillin as well as in dentis...

CAS 1744-22-5 Riluzole

Riluzole
(CAS: 1744-22-5)

Riluzole is a drug used to treat amyotrophic lateral sclerosis.

AZD-3161
(CAS: 1369501-46-1)

AZD 3161 is a Nav1.7-voltage-gated-sodium-channel-inhibitor originated by AstraZeneca. Phase-I clinical trials in Pain and Neuropathic pain was discontinued.

CAS 74517-78-5 Indecainide

Indecainide
(CAS: 74517-78-5)

Indecainide is a Sodium channel antagonists originated by Eli Lilly. Treatment for Arrhythmias and Ventricular arrhythmias was discontinued.

CAS 42971-09-5 Vinpocetine

Vinpocetine
(CAS: 42971-09-5)

Vinpocetine is a Phosphodiesterase inhibitor and selective for PDE1. It also blocks voltage-gated Na+ channels.

CAS 66794-74-9 Encainide Hydrochloride

Encainide Hydrochloride
(CAS: 66794-74-9)

Encainide Hydrochloride is a sodium channel blocker and class Ic antiarrhythmic agent. It is a non-chiral and benzanilide derivative. It blocks voltage-gated so...

VX-150

VX-150 is a NaV1.8 blocker which is currently in a phase II clinical trial for the treatment of patients with acute pain. Study shows that VX-150 significantly ...

CAS 892546-37-1 PH-064

PH-064
(CAS: 892546-37-1)

PH-064 is a sodium channel inhibitor. It is extracted from patent FR 2879460 A1.

CAS 34183-22-7 Propafenone hydrochloride

Propafenone hydrochloride
(CAS: 34183-22-7)

Propafenone is a Class 1C antiarrhythmic as sodium channel blocker by slowing the influx of sodium ions into the cardiac muscle cells.

Evenamide
(CAS: 1092977-61-1)

Evenamide is a selective voltage-gated sodium and​/or calcium channel modulator, including subtypes Nav1.3, Nav1.7, and Nav1.8. It may be potentia useful in pre...

CAS 1443373-17-8 AM-2099

AM-2099
(CAS: 1443373-17-8)

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 (IC50= 0.16 μM) with excellent selectivity against hNav1.5 (IC50 > 30 uM).

CAS 95635-55-5 Ranolazine

Ranolazine
(CAS: 95635-55-5)

Ranolazine is a calcium uptake inhibitor via the sodium/calcium channal, used to treat chronic angina.

CAS 298-46-4 Carbamazepine

Carbamazepine
(CAS: 298-46-4)

Carbamazepine (Carbatrol) is a sodium channel blocker with IC50 of 131 μM in rat brain synaptosomes.Carbamazepine (CBZ), first marketed under the tradename Tegr...

CAS 1722-62-9 Mepivacaine HCl

Mepivacaine HCl
(CAS: 1722-62-9)

Mepivacaine is a tertiary amine used as a local anesthetic.

CAS 5875-06-9 Proxymetacaine hydrochloride

Proxymetacaine hydrochloride
(CAS: 5875-06-9)

Proparacaine Hydrochloride is a topical ophthalmic anesthetic, acting by inhibiting the voltage-gated sodium channels. IC50(ED50): 3.4 mM.

Eleclazine
(CAS: 1443211-72-0)

Eleclazine is a selective Sodium channel antagonist. Eleclazin showed a shortening of the QTc interval (the time interval between the start of the Q-wave and en...

AM-36
(CAS: 199467-52-2)

AM-36 is a potent blocker of batrachotoxinin (BTX)-sensitive Na+ channel binding in rat brain homogenates with an IC50 of 0.28 microM. As a unique neuroprotecti...

Funapide
(CAS: 1259933-16-8)

Funapide is a Nav1.7 and Nav1.8 voltage-gated sodium channel inhibitor under the development by Xenon Pharmaceuticals and Teva Pharmaceutical Industries. It is ...

CAS 2016-88-8 Amiloride HCl

Amiloride HCl
(CAS: 2016-88-8)

Amiloride HCl is a relatively selective inhibitor of the epithelial sodium channel (ENaC), used in the management of hypertension and congestive heart failure.

Chemical Structure

CAS 74517-78-5 Indecainide

Quick Inquiry

Verification code

Featured Items